May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Association Between Beta 1 and Beta 2 Adrenergic Receptor Polymorphisms and Susceptibility to Primary Open Angle Glaucoma
J. A. Ayala-Haedo; S. M. Gerzenstein; J. C. Schiffman; D. L. Budenz; J. L. Davis; J. S. Schuman; S. G. Schwartz; L. M. Ventura; M. E. Fini; Miami Glaucoma Genetics Team
Author Affiliations & Notes
  • J. A. Ayala-Haedo
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • S. M. Gerzenstein
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • J. C. Schiffman
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • D. L. Budenz
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • J. L. Davis
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • J. S. Schuman
    UPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • S. G. Schwartz
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • L. M. Ventura
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • M. E. Fini
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • Miami Glaucoma Genetics Team
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • Footnotes
    Commercial Relationships J.A. Ayala-Haedo, None; S.M. Gerzenstein, None; J.C. Schiffman, None; D.L. Budenz, None; J.L. Davis, Bausch & Lomb, C; J.S. Schuman, Alcon; Allergan; Carl Zeiss Meditec, Inc; Merck; Optovue; Heidelberg Engineering, F; Carl Zeiss Meditec, Inc;, P; Alcon; Allergan; Carl Zeiss Meditec,Inc; Clarity; Merck; Heidelberg Engineering, R; S.G. Schwartz, Genentech, F; Pfizer, I; Novartis, R; L.M. Ventura, None; M.E. Fini, None.
  • Footnotes
    Support NIH center grant P30 EY014801 and unrestricted grant to the University of Miami from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4035. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Association Between Beta 1 and Beta 2 Adrenergic Receptor Polymorphisms and Susceptibility to Primary Open Angle Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. A. Ayala-Haedo, S. M. Gerzenstein, J. C. Schiffman, D. L. Budenz, J. L. Davis, J. S. Schuman, S. G. Schwartz, L. M. Ventura, M. E. Fini, Miami Glaucoma Genetics Team; Association Between Beta 1 and Beta 2 Adrenergic Receptor Polymorphisms and Susceptibility to Primary Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4035.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: It has been demonstrated that SNPs affect the activity and expression of beta adrenergic receptors. The +1165G/C (Arg389Gly) SNP in the Beta 1 adrenergic receptor gene has been reported to increase the risk of glaucoma. We hypothesized that additional SNPs in either the Beta 1 and Beta 2 adrenergic receptor gene might also increase the risk of primary open angle glaucoma (POAG).

Methods:: We enrolled 189 Caucasian subjects for the study. The samples were studied using the iPLEX genotyping assay from Sequenom. For the Beta 1 adrenergic receptor gene we analyzed 63 POAG and 121 controls for the +145A/G (Ser49Gly) SNP and 36 POAG and 57 controls for the +1165G/C (Arg389Gly) SNP. For the Beta 2 Adrenergic receptor gene we analyzed 67 POAG and 122 controls for the eleven SNPs:-1429T/A, -1343G/A, -1023G/A, -654G/A, -468C/G,- 367T/C, -47T/C,-20C/T, +46G/A (Arg16Gly), +79C/G (Gln27Glu), +491C/T(Thr164Ile), using chi-square and logistic regression.

Results:: In the Beta 1 receptor gene, for the +145A/G SNP, the genotype AA was present in 68% of the POAG patients and 81% of the controls; genotype GA in 29% of the POAG patients and 19% of the controls; and GG in 3% of the POAG patients and none of the controls, (p=0.025). The frequency of each genotype was similar in POAG patients and controls for the +1165G/C SNP: CC in 53% POAG vs. 46% controls; GC in 8% POAG vs. 16% controls; and GG in 39% POAG vs. 39% controls (p=0.73). For all eleven SNPs in the Beta 2 receptor gene, the frequency of each genotype was remarkably similar in the POAG patients and normal controls: for six of the SNPs the frequency of each genotype was within 5% between POAG and controls; for four the frequency was within 10%; and for one the largest difference was 13% (p-values ranged from 0.22 to 0.97).

Conclusions:: Our results support the hypothesis that the Beta 1 receptor gene polymorphism +145A/G, but not +1165G/C, is associated with POAG. We found no evidence of an association of POAG with any of the Beta 2 polymorphisms in this Caucasian population. In this pilot study, controls were not perfectly age-matched to patients; therefore we continue to enroll subjects before arriving to a final conclusion.

Keywords: genetics • gene screening • candidate gene analysis 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept